Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey

Vavricka, Stephan R; Schoepfer, Alain M; Bansky, Georg; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Scharl, Michael; Seibold, Frank; Straumann, Alex; Michetti, Pierre; Swiss IBDnet, (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory bowel diseases, 17(7), pp. 1530-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21521

Full text not available from this repository. (Request a copy)

Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Seibold, Frank Werner

ISSN:

1078-0998

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:22

Last Modified:

17 Mar 2015 21:01

Publisher DOI:

10.1002/ibd.21521

PubMed ID:

21674709

Web of Science ID:

000292415200008

URI:

https://boris.unibe.ch/id/eprint/7747 (FactScience: 213073)

Actions (login required)

Edit item Edit item
Provide Feedback